TEVA PHARMA INDUSTRIES LTD ADR (NYSE: TEVA)

TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

最近更新时间: 昨天, 10:38AM

35.96

-0.29 (-0.80%)

加入群组

前收盘价格	36.25
收盘价格	36.18
成交量	2,836,258
平均成交量 (3个月)	11,776,652
市值	41,256,280,064

市盈率 (P/E TTM)	29.72
预期市盈率 (P/E Forward)	11.20
价格/销量 (P/S)	2.19
股市价格/股市净资产 (P/B)	5.03

52周波幅	12.47 (-65%) — 37.35 (3%)
利润日期	28 Jan 2026

市场趋势

		短期	中期
行业	Drug Manufacturers - Specialty & Generic (US)	混合的	看涨
	Drug Manufacturers - Specialty & Generic (全球的)	混合的	看涨
股票	Teva Pharmaceutical Industries	看涨	看涨

AIStockmoo 评分

0.8

分析师共识	1.5
内部交易活动	NA
价格波动	-3.0
技术平均移动指标	2.5
技术振荡指标	2.0
平均	0.75

相关股票

股票	市值	DY	P/E（TTM）	P/B
TEVA	41 B	-	29.72	5.03
TAK	56 B	4.61%	77.03	1.08
HLN	48 B	1.08%	23.51	2.08
RDY	12 B	54.73%	18.61	2.76
ZTS	56 B	0.79%	21.38	10.22
HIMS	6 B	-	46.68	10.61

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
部门	Healthcare
行业	Drug Manufacturers - Specialty & Generic
投资方式	Large Value
机构持股比例	67.15%

所有权

姓名	日期	持有股份
Harel Insurance Investments & Financial Services Ltd.	31 Dec 2025	44,951,773
Phoenix Financial Ltd.	30 Sep 2025	41,295,244
Menora Mivtachim Holdings Ltd.	30 Sep 2025	38,920,294
Migdal Insurance & Financial Holdings Ltd.	31 Dec 2025	37,402,212
Clal Insurance Enterprises Holdings Ltd	30 Sep 2025	31,486,683
Lingotto Investment Management Llp	30 Sep 2025	28,588,790
Rubric Capital Management Lp	30 Sep 2025	24,650,000
Pointstate Capital Lp	30 Sep 2025	20,712,398
Glenview Capital Management, Llc	30 Sep 2025	16,692,680
Duquesne Family Office Llc	30 Sep 2025	16,593,935
Altshuler Shaham Ltd	30 Sep 2025	8,297,424

52周波幅	12.47 (-65%) — 37.35 (3%)
目标价格波幅	32.00 (-11%) — 40.00 (11%)
高	40.00 (Jefferies, 11.24%)	购买
	40.00 (Scotiabank, 11.24%)	购买
	40.00 (Piper Sandler, 11.24%)	购买
中	38.00 (5.67%)
低	32.00 (B of A Securities, -11.01%)	购买
平均值	37.25 (3.59%)
总计	8 购买
平均价格@调整类型	31.57

公司	日期	目标价格	调整类型	价格@调整类型
Barclays	30 Jan 2026	38.00 (5.67%)	购买	34.08
Barclays	09 Dec 2025	35.00 (-2.67%)	购买	28.56
Scotiabank	29 Jan 2026	40.00 (11.23%)	购买	33.07
Scotiabank	05 Dec 2025	35.00 (-2.67%)	购买	28.46
Truist Securities	29 Jan 2026	38.00 (5.67%)	购买	33.07
Jefferies	06 Jan 2026	40.00 (11.23%)	购买	32.11
Piper Sandler	22 Dec 2025	40.00 (11.23%)	购买	31.21
Goldman Sachs	19 Dec 2025	35.00 (-2.67%)	购买	30.35
Goldman Sachs	08 Dec 2025	31.00 (-13.79%)	购买	28.33
JP Morgan	16 Dec 2025	35.00 (-2.67%)	购买	30.10
JP Morgan	06 Nov 2025	28.00 (-22.14%)	购买	24.46
B of A Securities	09 Dec 2025	32.00 (-11.01%)	购买	28.56
显示更多

该时间范围内无数据。

日期	类型	细节
28 Jan 2026	公告	Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28 Jan 2026	公告	Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
27 Jan 2026	公告	Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27 Jan 2026	公告	Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
14 Jan 2026	公告	AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
14 Jan 2026	公告	AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
11 Jan 2026	公告	Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026	公告	Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026	公告	Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026	公告	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
11 Jan 2026	公告	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
07 Jan 2026	公告	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
05 Jan 2026	公告	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
05 Jan 2026	公告	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
24 Dec 2025	公告	S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
24 Dec 2025	公告	S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
23 Dec 2025	公告	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
19 Dec 2025	公告	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025	公告	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025	公告	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
17 Dec 2025	公告	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
16 Dec 2025	公告	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12 Dec 2025	公告	Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025	公告	Teva Releases Q4 2025 Aide Memoire
12 Dec 2025	公告	Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025	公告	Teva Releases Q4 2025 Aide Memoire
09 Dec 2025	公告	Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09 Dec 2025	公告	Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
25 Nov 2025	公告	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
25 Nov 2025	公告	Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
25 Nov 2025	公告	Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
21 Nov 2025	公告	Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
21 Nov 2025	公告	Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
19 Nov 2025	公告	Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
19 Nov 2025	公告	Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
12 Nov 2025	公告	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
07 Nov 2025	公告	AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
07 Nov 2025	公告	AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
05 Nov 2025	公告	Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
05 Nov 2025	公告	Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
显示更多

5年平均股息收益率

0.00%

除息日	公告日期	支付日期	详情
27 Nov 2017	06 Nov 2017	12 Dec 2017	0.085 现金
25 Aug 2017	-	14 Sep 2017	0.07225 现金
01 Jun 2017	-	22 Jun 2017	0.289 现金
28 Feb 2017	-	20 Mar 2017	0.289 现金
01 Dec 2016	-	20 Dec 2016	0.289 现金
18 Aug 2016	-	08 Sep 2016	0.289 现金
20 May 2016	-	07 Jun 2016	0.289 现金
25 Feb 2016	-	14 Mar 2016	0.289 现金
13 Nov 2015	-	03 Dec 2015	0.289 现金
18 Aug 2015	-	03 Sep 2015	0.289 现金
15 May 2015	-	04 Jun 2015	0.289 现金
17 Feb 2015	-	03 Mar 2015	0.293636 现金
13 Nov 2014	-	02 Dec 2014	0.269593 现金
19 Aug 2014	-	04 Sep 2014	0.291112 现金
16 May 2014	-	02 Jun 2014	0.29777 现金
20 Feb 2014	-	10 Mar 2014	0.293019 现金
18 Nov 2013	-	03 Dec 2013	0.277541 现金
16 Aug 2013	-	03 Sep 2013	0.273656 现金
16 May 2013	-	03 Jun 2013	0.268249 现金
19 Feb 2013	-	07 Mar 2013	0.266857 现金
13 Nov 2012	-	03 Dec 2012	0.202399 现金
13 Aug 2012	-	04 Sep 2012	0.208281 现金
17 May 2012	-	04 Jun 2012	0.196042 现金
23 Feb 2012	-	13 Mar 2012	0.197212 现金
10 Nov 2011	-	07 Dec 2011	0.17539 现金
09 Nov 2011	-	07 Dec 2011	0.171904 现金
04 Aug 2011	-	25 Aug 2011	0.196304 现金
03 Aug 2011	-	25 Aug 2011	0.199624 现金
19 May 2011	-	07 Jun 2011	0.199925 现金
10 Feb 2011	-	07 Mar 2011	0.216813 现金
08 Nov 2010	-	06 Dec 2010	0.173008 现金
02 Aug 2010	-	26 Aug 2010	0.166994 现金
10 May 2010	-	04 Jun 2010	0.163153 现金
19 Feb 2010	-	17 Mar 2010	0.164033 现金
06 Nov 2009	-	04 Dec 2009	0.125431 现金
03 Aug 2009	-	27 Aug 2009	0.124804 现金
08 May 2009	-	03 Jun 2009	0.120261 现金
23 Feb 2009	-	19 Mar 2009	0.111992 现金
07 Nov 2008	-	05 Dec 2008	0.09309 现金
01 Aug 2008	-	27 Aug 2008	0.10421 现金
13 May 2008	-	05 Jun 2008	0.11255 现金
12 May 2008	-	05 Jun 2008	0.10919 现金
18 Feb 2008	-	13 Mar 2008	0.10429 现金
15 Feb 2008	-	13 Mar 2008	0.10174 现金
02 Nov 2007	-	28 Nov 2007	0.084 现金
10 Aug 2007	-	06 Sep 2007	0.08015 现金
10 May 2007	-	05 Jun 2007	0.0833 现金
16 Feb 2007	-	15 Mar 2007	0.07866 现金
10 Nov 2006	-	06 Dec 2006	0.06569 现金
11 Aug 2006	-	08 Sep 2006	0.06434 现金
12 May 2006	-	07 Jun 2006	0.06257 现金
06 Mar 2006	-	30 Mar 2006	0.06072 现金
10 Nov 2005	-	07 Dec 2005	0.05188 现金
11 Aug 2005	-	07 Sep 2005	0.05431 现金
05 May 2005	-	01 Jun 2005	0.0559 现金
17 Feb 2005	-	17 Mar 2005	0.0559 现金
09 Nov 2004	-	06 Dec 2004	0.0414 现金
09 Aug 2004	-	07 Sep 2004	0.0401 现金
10 May 2004	-	07 Jun 2004	0.0768 现金
20 Feb 2004	-	22 Mar 2004	0.0781 现金
13 Nov 2003	-	12 Dec 2003	0.0587 现金
08 Aug 2003	-	08 Sep 2003	0.0596 现金
08 May 2003	-	06 Jun 2003	0.0581 现金
24 Feb 2003	-	24 Mar 2003	0.0546 现金
07 Nov 2002	-	06 Dec 2002	0.0738 现金
19 Aug 2002	-	16 Sep 2002	0.0738 现金
20 May 2002	-	17 Jun 2002	0.0701 现金
15 Feb 2002	-	18 Mar 2002	0.0772 现金
16 Nov 2001	-	17 Dec 2001	0.0531 现金
20 Aug 2001	-	17 Sep 2001	0.0498 现金
17 May 2001	-	15 Jun 2001	0.0486 现金
08 Mar 2001	-	06 Apr 2001	0.0477 现金
16 Nov 2000	-	15 Dec 2000	0.0407 现金
24 Aug 2000	-	21 Sep 2000	0.0415 现金
19 May 2000	-	19 Jun 2000	0.0405 现金
17 Feb 2000	-	27 Mar 2000	0.0838 现金
04 Nov 1999	-	30 Nov 1999	0.0529 现金
18 Aug 1999	-	13 Sep 1999	0.0527 现金
21 May 1999	-	15 Jun 1999	0.054 现金
08 Mar 1999	-	30 Mar 1999	0.055 现金
20 Nov 1998	-	11 Dec 1998	0.053 现金
21 Aug 1998	-	11 Sep 1998	0.058 现金
21 May 1998	-	22 Jun 1998	0.0639 现金
12 Mar 1998	-	31 Mar 1998	0.0649 现金
20 Nov 1997	-	09 Dec 1997	0.0666 现金
25 Aug 1997	-	11 Sep 1997	0.0667 现金
23 May 1997	-	12 Jun 1997	0.069 现金
07 Mar 1997	-	26 Mar 1997	0.0695 现金
20 Nov 1996	-	09 Dec 1996	0.0468 现金
26 Aug 1996	-	12 Sep 1996	0.0492 现金
23 May 1996	-	12 Jun 1996	0.0477 现金
07 Mar 1996	-	26 Mar 1996	0.0504 现金
20 Nov 1995	-	07 Dec 1995	0.0485 现金
14 Aug 1995	-	30 Aug 1995	0.0488 现金
17 May 1995	-	07 Jun 1995	0.051 现金
07 Mar 1995	-	04 Apr 1995	0.0512 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2017	0.735	4	3.88
2016	1.16	4	3.19
2015	1.16	4	1.77
2014	1.15	4	2.00
2013	1.09	4	2.71
2012	0.804	4	2.15
2011	1.16	6	2.87
2010	0.667	4	1.28
2009	0.482	4	0.86
2008	0.625	6	1.47
2007	0.326	4	0.70
2006	0.253	4	0.82
2005	0.218	4	0.51
2004	0.236	4	0.79
2003	0.231	4	0.82
2002	0.295	4	1.53
2001	0.199	4	1.29
2000	0.207	4	1.13
1999	0.215	4	2.40
1998	0.240	4	4.72
1997	0.272	4	4.60
1996	0.194	4	3.09
1995	0.200	4	3.44
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2026	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	-7.74%
营业利益率 (TTM)	18.22%
稀释每股收益 (EPS TTM)	-1.15
季度收入增长率 (YOY)	1.90%

总债务/股东权益 (D/E MRQ)	270.20%
流动比率 (MRQ)	1.03
营业现金流 (OCF TTM)	1.27 B
杠杆自由现金流 (LFCF TTM)	1.66 B

资产报酬率 (ROA TTM)	5.27%
股东权益报酬率 (ROE TTM)	-19.11%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)